CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

IDENTIFIER (ClinicalTrials.gov): NCT07087054

DRUG/TREATMENT: Paltusotine

PHASE: 3

STATUS: Recruiting

SPONSOR: Crinetics Pharmaceuticals Inc.

DESCRIPTION:

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to  view this trial here.

MORE INFORMATION

For more information about the CAREFNDR clinical study, visit CAREFNDR.com/ncf.

Global enrollment in CAREFNDR is expected throughout 2025 and 2026.

Read this recent press release: "Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome"

CONTACT

Crinetics Clinical Trials

EMAIL: clinicaltrials@crinetics.com

PHONE: 833-276-4636

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.